DiaMedica Therapeutics
Manufacturing · Minnesota, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
301 Carlson Pkwy Ste 210, Minneapolis, M...Phone Number
(763) 496-5454Website
www.diamedica.comRevenue
$22.4 MillionStock Symbol
DMACIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedicas lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases.Explore more
DiaMedica Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DiaMedica Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
DiaMedica Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if DiaMedica Therapeutics is spiking on competitors!
Check if DiaMedica Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when DiaMedica Therapeutics launches new products
Funding: Get notified immidiatlly once DiaMedica Therapeutics has new funding data
Click to see if DiaMedica Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on DiaMedica Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at DiaMedica Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to DiaMedica Therapeutics
Compare insights from companies similar to DiaMedica Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
DiaMedica Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
DiaMedica Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about DiaMedica Therapeutics.
DiaMedica Therapeutics financials insights
Gather financial insights about DiaMedica Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Stock Offering
$5.5M
2025
Stock/Share Issuance
$30.1M
Private Equity
$30.1M
DiaMedica Therapeutics Tech Stack
A closer look at the technologies used by DiaMedica Therapeutics
Most Recent Scoops
Hiring Plans
DiaMedica Therapeutics has more open roles in Medical & Health than it has had at any time in the past 12 months.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Person-Based
DiaMedica Therapeutics News & Media
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call March 31, 2026 8:00 AM EDTCompany ParticipantsDietrich Pauls - President, CEO & DirectorJulie...DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer - Stock Titan
Former PureTech CMO Julie Krop joins DiaMedica as it advances DM199 for preeclampsia treatment. Learn how her expertise could accelerate development. See details.DiaMedica Therapeutics Secures $30.1 Million in Private Placement - TipRanks.com
Diamedica Therapeutics ( ($DMAC) ) has issued an announcement. DiaMedica Therapeutics has successfully closed a $30.1 million private placement of common shares, en...DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry ...
MINNEAPOLIS, July 21, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by current investors. No placement agent was engaged for this transaction.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DiaMedica Therapeutics
Sign Up For FreeTo access detailed company insights
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedicas lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treat... Read More
